EPISODE · May 7, 2026 · 11 MIN
Vepdegestrant
from OncoPharm · host John Bossaer
The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated breast cancer. We discuss what that actually means and some possible implications for clinical practice. Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm
Embed this episode
Ready to play
Vepdegestrant
0:00
11:35
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of OncoPharm?
This episode is 11 minutes long.
When was this OncoPharm episode published?
This episode was published on May 7, 2026.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!